Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Single-arm Study of Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Treated With Neoadjuvant Concurrent Chemoradiotherapy Followed by Curative Resection

Next Previous
X
Search
Trial Profile

Phase II, Single-arm Study of Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Treated With Neoadjuvant Concurrent Chemoradiotherapy Followed by Curative Resection

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Cisplatin; Paclitaxel
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Sep 2021 Results (N=37) of an analysis of updated follow up data till cutoff date of March 31st, 2021, presented at the 2021 World Conference on Lung Cancer
    • 10 Sep 2019 Results (data cut off 20th of January, 2019; n=37) presented at the 20th World Conference on Lung Cancer.
    • 04 Jun 2019 Results assessing clinical efficacy of pembrolizumab treatment after CCRT and curative resection in patients with non-small cell lung cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top